Yahoo Finance

Insider Ownership: 25.9%

Revenue Growth Forecast: 15.4% p.a.

Anton Oilfield Services Group is trading significantly below its estimated fair value, with earnings projected to grow substantially at 23.6% annually, surpassing the Hong Kong market's growth rate. Despite a recent decline in sales to CNY 146.51 million, revenue and net income have increased year-over-year. The company's Return on Equity forecast remains low at 9.5%, yet insider ownership stability may attract investors amid strategic board changes and a proposed dividend of RMB 0.025 per share for 2024.

• Unlock comprehensive insights into our analysis of Anton Oilfield Services Group stock in this growth report.

• Our expertly prepared valuation report Anton Oilfield Services Group implies its share price may be lower than expected.

Ascentage Pharma Group International

Simply Wall St Growth Rating: ★★★★★★

Overview: Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China, with a market cap of HK$12.61 billion.

Operations: The company's revenue primarily comes from the development and sale of novel small-scale therapies, amounting to CN¥903.03 million.

Insider Ownership: 17.9%

Revenue Growth Forecast: 22.9% p.a.

Ascentage Pharma Group International shows promising growth potential with a significant increase in sales from CNY 221.98 million to CNY 980.65 million year-over-year, while reducing its net loss substantially. Its pipeline of innovative cancer therapies, including drugs with Breakthrough Therapy Designations in China, highlights its strategic focus on unmet medical needs. Although shareholders faced dilution recently, the company's high insider ownership and expected profitability within three years suggest strong alignment with long-term growth objectives.

• Take a closer look at Ascentage Pharma Group International's potential here in our earnings growth report.

• According our valuation report, there's an indication that Ascentage Pharma Group International's share price might be on the expensive side.

Make It Happen

• Navigate through the entire inventory of 648 Fast Growing Asian Companies With High Insider Ownership here.

• Looking For Alternative Opportunities? AI is about to change healthcare. These 24 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include SEHK:1405 SEHK:3337 and SEHK:6855.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com